AnHeart Therapeutics

AnHeart Therapeutics

    Company info:

  • 1-50
  • 2018
  • New York, NY
  • 50-100M

Claim company profile

About company:

AnHeart Therapeutics is developing novel precision oncology therapeutics for areas of unmet clinical need. AnHeart’s lead candidate, taletrectinib, is currently in Phase 2 trials in a subset of patients with non-small cell lung cancer (NSCLC). Taletrectinib inhibits the protein ROS1, which is mutated in ~2% of NSCLC patients and several other cancers. While first generation ROS1 inhibitors exist, there are patients who are resistant to treatment due to treatment-resistant mutations. AnHeart developed Taletrectinib to show potency against resistance tumors and has so far shown a strong safety profile and can pass the blood brain barrier with potential to address brain metastasis. AnHeart is also advancing many other precision oncology clinical programs.


AnHeart Therapeutics
All jobs
See jobs

Claim company profile to post jobs directly on this page and this website.

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy